CTVA · Q4 2025 Earnings

Bullish

Corteva

Reported February 3, 2026

30-second summary

Corteva closed FY2025 at $17.4B revenue (+2.9%) and $3.34 non-GAAP EPS — above the August-raised $3.00–$3.20 FY range — with operating EBITDA of $3.848B landing at the high end of the $3.75–$3.85B guide, and posted $2.87B free cash flow, blowing past the ~$1.9B guide by ~$1.0B. The bigger story is forward: management guided FY2026 operating EPS to $3.45–$3.70 and EBITDA to $4.0–$4.2B (+7% YoY at midpoint), and disclosed a Bayer FTO settlement that pulls corn licensing forward five years to 2027, achieves royalty neutrality two years early in 2026, and opens a US cotton licensing market Corteva did not previously address — sized at ~$1B aggregate earnings upside over the decade.

Headline numbers

EPS

Q4 FY2025

$0.22

Revenue

Q4 FY2025

$3.91B

-1.7% YoY

Gross margin

Q4 FY2025

42.4%

Operating margin

Q4 FY2025

-13.5%

Key financials

Q4 FY2025

Metric	Q4 FY2025	YoY	Q3 FY2025	QoQ
Revenue	$3.91B	-1.7%	$2.62B	+49.4%
EPS	$0.22	—	$-0.23	+195.7%
Gross margin	42.4%	—	37.2%	+520bps
Operating margin	-13.5%	—	—	—

Guidance

FY2026 Operating EPS and EBITDA guidance raised substantially (+14% midpoint EPS, +6-9% midpoint EBITDA) following FY2025 results that missed EPS but exceeded Free Cashflow expectations.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Revenue	Q4 FY2025	Not explicitly guided	$3.91 billion	in-line	Met
Non-GAAP EPS	Q4 FY2025	Not explicitly guided	$0.22	in-line	Met

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Operating EPS	FY2026	$3.00 to $3.20	$3.45 to $3.70	+$0.45 to +$0.50 at range midpoints (+14% midpoint increase)	Raised
Operating EBITDA	FY2026	$3.75 billion to $3.85 billion	$4.00 billion to $4.20 billion	+$0.25 to +$0.35 billion at range endpoints (+6-9% midpoint increase)	Raised
Free Cashflow	FY2025	approximately $1.9 billion	$2.866 billion	+$0.966 billion vs. prior guide (+51%)	Raised
Net Cost Improvement Target	FY2025	$450 million	Withdrawn — no replacement	—	Withdrawn
Operating EBITDA Margin Expansion	FY2025	approximately 150 basis points	Withdrawn — no replacement	—	Withdrawn

Segment KPIs

Q4 FY2025

Segment	Q4 FY2025	YoY
Seed - Corn	$1.386B	-1.8%
Seed - Soybean	$0.164B	+6.5%
Seed - Other Oilseeds	$0.094B	+8.1%
Seed Total	$1.737B	-1.9%
Crop Protection - Herbicides	$1.062B	+3.0%
Crop Protection - Insecticides	$0.488B	-0.4%
Crop Protection - Fungicides	$0.272B	-15.0%
Crop Protection - Biologicals	$0.191B	+13.0%
Crop Protection Total Revenue	$2,173M	—

Other KPIs

Q4 FY2025

Segment	Q4 FY2025
Seed Segment Operating EBITDA	$124M
Crop Protection Segment Operating EBITDA	$360M
Operating EBITDA (Total)	$446M
Organic Sales Change	-4.1%
North America Revenue	$1,478M
EMEA Revenue	$424M
Latin America Revenue	$1,653M

Management tone

Q2 anchor: cost-program acceleration → Q4 anchor: Bayer FTO unlock and licensing pivot.

The Bayer settlement collapses a multi-year overhang into a quantified growth lever. What had been framed in Q2 as an "interesting strategic pivot" toward out-licensing — sized at $4B globally — became, in this quarter, a concrete agreement worth "about a billion of aggregate earnings upside for Corteva across our corn, cotton, and canola portfolios" (per the call summary). Corn licensing accelerated from a 2030s commercial event to 2027 — a five-year pull-forward — and US cotton licensing is now an addressable market Corteva did not previously participate in. This is the most consequential commercial disclosure since separation.

Royalty neutrality moved from "by 2028" to "in 2026." In Q2 management pulled the royalty-neutrality target forward from 2030 to 2028 and treated that as the headline. One quarter later, it's 2026: management quantified a $120M total net royalty improvement in FY2026, of which the Bayer agreement accelerates a portion (pulling royalty neutrality two years forward), with an incremental $100M+ annual benefit from Bayer kicking in past 2027. The drag that defined the seed P&L since separation is structurally gone — two years ahead of the August timeline and four ahead of the original.

Crop Protection outlook flipped from "stabilizing" to "modest growth." Through 2024 and early 2025, CP commentary was about destocking, generic-pricing stabilization, and volume-led recovery against price headwinds. This quarter management used a phrase that wouldn't have appeared in prior calls: "we are expecting modest growth in 2026, something we haven't seen in a while." Combined with stabilized China generic pricing now extending into a sixth quarter, this signals the cyclical bottom is past.

Separation timing crystallized. Q2 referenced a 2026 separation; this quarter management committed to "second half separation, most likely sometime in the fourth quarter," with Investor Day in mid-September and executive leadership teams to be announced. The shift from "we're separating" to a dated calendar materially reduces execution uncertainty — but also introduces the ~$100M dissynergy figure that wasn't in prior framing.

Growth rate concedes deceleration despite raised dollar guidance. Q2 talked about "double-digit bottom-line growth" for FY2025; the FY2026 guide is +7% EBITDA at midpoint. The dollar level is higher, the growth rate is roughly half. Management did not lean into this softening, but it sits inside the raise.

Recurring themes management leaned on this quarter:

Bayer FTO resolution unlocking licensing acceleration and new market entrySeed licensing business ramp-up driving royalty neutrality ahead of scheduleCrop protection market inflection to modest growth in 2026Margin expansion through productivity benefits and cost disciplineSeparation progress and timeline clarity for two independent companiesStrong cash generation and shareholder returns discipline

Risks management surfaced:

Competitive pricing dynamics in Latin America and Asia PacificCurrency headwinds (Brazil Real, Canadian Dollar, Turkish Lira)Tariff headwinds of approximately $80 million expected in 2026Net dissynergies estimated at roughly $100 million from separationWeather and timing shifts affecting seasonal deliveries

Q&A highlights

Chris Parkinson · Wolf Research

Request for breakdown of Bayer litigation settlement on slide 27, specifically how it affects acceleration of E3/Concasta and whether the chart assumes gene editing implications.

Management explained the agreement provides freedom to operate and increased licensing market access, accelerating corn licensing to 2027 (years ahead of original plans) and enabling entry into cotton licensing. Triple stack options accelerated 5 years, third-gen product 2 years forward. HT4 licensing from Bayer and Enlist Cotton provision create additional opportunity.

~$1 billion in licensing income expected over next decadeCorn licensing accelerated to 2027Triple stack options brought to market 5 years earlierThird-gen above ground product 2 years forward

Vincent Andrews · Morgan Stanley

Clarification on existing licensing expense being eliminated by $610M payment and whether HT4 license carries future per-acre royalties or is included in flat payment.

Management confirmed $120M net royalty benefit in 2026 from eliminated Bayer royalties, achieving net neutral position 2 years ahead. Rest of benefit comes post-2027 with $100M+ annual benefit. HT4 is not royalty-free; Corteva will pay royalties on HT4 usage, with reciprocal royalty arrangement with Bayer.

$120 million net royalty benefit in 2026Achieves net neutral position 2 years ahead of plan$100+ million annual benefit after 2027HT4 requires ongoing royalty payments (not royalty-free)

Kevin McCarthy · Radical Research

Expected timeline for EU gene-editing regulatory framework adoption and medium/long-term implications; update on multi-disease resistant corn commercialization timeline.

Management expects EU framework formal adoption by first half of 2026 and views it as science-based and practical. Still awaiting China approval. Gene-edited fungal disease resistant corn with disease super locus expected to commercialize within 1-2 years after regulatory approval, first in US then globally. Emphasized gene editing as critical technology for improving farmer profitability.

EU gene-editing framework expected formal adoption H1 2026China approval still pendingDisease-resistant corn commercialization within 1-2 years post-approvalUS market first, then global expansion

Duffy Fisher · Goldman Sachs

Market share performance by crop and geography in 2025; clarification on whether Bayer receives access to Enlist soybeans.

North America: share gains in corn and soy. Latin America: mid-single-digit share gains in corn and sunflower. India: recovery in rainy season corn. EMEA: share gains in sunflower and corn. E3 soybeans specifically NOT part of Bayer agreement discussions. Positive impacts across almost all regions.

Share gains in North American corn and soybeansMid-single-digit share gains in Latin American summer cornMid-single-digit plus share gains in Brazilian safflowerRecovery in Indian rainy season corn

Answers to last quarter's watch list

Seed Latin America recovery in Q3/Q4. LatAm revenue overall was $1.65B in Q4 (+1.9% YoY), the largest geography by some margin; mid-single-digit share gains in LatAm summer corn and Brazilian sunflower were specifically called out by management in Q&A. Seed Q4 total was −1.9% YoY but the LatAm-specific deceleration from Q2 has eased; Brazil planting calendar normalized vs Q2's timing-shift drag. Status: Resolved positively

Crop Protection pricing in Brazil during H2. CP herbicides +3% and biologicals +13% offset fungicide weakness (−15%); management characterized China generic pricing as stable into a sixth quarter and guided 2026 as modest CP market growth — the first such call in years. Status: Resolved positively

Cost program execution beyond $450M. FY2025 EPS of $3.34 came in above the raised $3.00–$3.20 range, implying the cost program over-delivered. For FY2026 management has now provided a $200M productivity target (split roughly evenly between Seed and CP), with ~$80M of tariff offset and ~$50M of in-year dissynergies — a step down from FY2025's ~$665M net cost benefit, half of which was commodity-driven and not repeating. Status: Resolved

Out-licensing revenue disclosure. The Bayer FTO settlement converted the out-licensing narrative into a quantified ~$1B aggregate earnings opportunity, with corn licensing accelerated to 2027 and US cotton licensing as a new addressable market. This is the explicit disclosure the prior watch asked for. Status: Resolved positively

Q4 working capital and FCF conversion. FY2025 free cash flow was $2.87B vs the ~$1.9B guide — a $0.97B beat (+51%). Cash conversion materially exceeded the ~50% implied by the guide. Status: Resolved positively

What to watch into next quarter

FY2026 productivity delivery net of tariffs. Management guided ~$200M of gross productivity savings against ~$80M of tariff headwind — a much smaller net contribution than FY2025. Watch Q1 commentary for whether the tariff number holds at $80M (almost entirely China CP actives into the US) and whether productivity tracks to the $200M run rate.

H1 phasing delivery. Management guided ~60% of sales and ~85% of EBITDA in H1 2026 — unusually front-loaded for a company that historically saw a more even split. A Q1 EBITDA print materially short of this phasing would call the FY2026 guide into question quickly.

Bayer settlement P&L mechanics in Q1. Watch the explicit isolation of the $120M net royalty benefit in Q1 results and whether the $610M settlement payment hits cash flow as expected — these are the cleanest tests of the settlement's quantified guide.

Separation milestones at September Investor Day. Executive leadership team announcements and the segment-by-segment go-forward financial framework will set the post-separation valuation anchors; watch whether the $100M dissynergy estimate holds or expands.

Crop Protection fungicides recovery. The −15% Q4 fungicide print is by far the worst single-product line in the deck; watch whether Q1 brings stabilization or whether this becomes a structural drag against the "modest CP growth" 2026 thesis.

FY2026 free cash flow guidance. No FCF dollar guide was provided for FY2026 despite the $2.87B FY2025 print; management framed conversion at 45–50% absent the Bayer payment and separation cash items. Watch for explicit disclosure on the Q1 call.

Sources

Corteva Q4 2025 Earnings Schedules, SEC Form 8-K (December 31, 2025 period): https://www.sec.gov/Archives/edgar/data/1755672/000175567226000002/a123125enrschedules.htm
Corteva Q4 2025 / FY2025 press release and management commentary on FY2026 guidance, Bayer FTO settlement, and separation timeline.

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.